Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1889)	4/3/2003 5:37:48 PM
From: Icebrg	Read Replies (2) \| Respond to of 2243

>> Spectrum Pharmaceuticals (SPPI)>> Spectrum had a fairly good day today gaining 60 cents closing at 2,80, which corresponds to a price increase of abt. 27 %. Turnover was impressive at 469.000 shares. That's about 16 % of the total number of shares outstanding. I have previously stated that the market cap. was only abt. 3,5 mUSD. That seems however to be on the low side. According to the recently filed 10K the number of outstanding shares is just below 3 mio. (Yahoo is somewhat behind, it seems). At todays closing price that translates into a market cap. of abt 8.4 mUSD, which is still not very much. As for the reason for the recent enthusiasm (the stock closed Tuesday at 2.01) there is not much I can suggest. Most probably they could announce that the FDA has accepted their first try to file an ANDA. For Cipro on behalf of their Indian partner. The next thing to look out for that I am aware of is the data that will be presented at ASCO with regard to Satraplatin. GPC Biotech has indicated that the data that BMY never bothered to look at is very good. At least it was good enough to convince the Germans to license the drug and elevate it to leading clinical drug status. Erik